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SEVERAL STUDIES HAVE SHOWNthat high residual platelet re-activity during clopidogreltreatment is predictive of major
cardiovascular events in patients under-
going percutaneous coronary interven-
tion (PCI).1-14 However, there is no stan-
dardized technique among ex vivo
platelet function tests, and in studies
using the same platelet function test,
cutoff values for high on-treatment
platelet reactivity established by receiver
operating characteristic curve analysis
are variable. Consequently, the hypoth-
esis that the risk of thrombotic events
increases markedly above a critical cut
point of platelet reactivity on in vitro
tests is not yet proven. Moreover, most
studies have included heterogeneous
populations with short follow-up, and
few data exist for patients with acute
coronary syndromes (ACS) undergo-
ing an invasive procedure. The Responsiveness to Clopidogrel
and Stent Thrombos i s 2–ACS
(RECLOSE 2–ACS) study tested the hy-
pothesis that high residual platelet re-For editorial comment see p 1260.
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Context High residual platelet reactivity (HRPR) in patients receiving clopidogrel has
been associated with high risk of ischemic events after percutaneous coronary inter-
vention (PCI).
Objective To test the hypothesis that HRPR after clopidogrel loading is an indepen-
dent prognostic marker of risk of long-term thrombotic events in patients with acute
coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treat-
ment adjusted according to the results of platelet function tests.
Design, Setting, and Patients Prospective, observational, referral center cohort
study of 1789 consecutive patients with ACS undergoing PCI from April 2005 to April
2009 at the Division of Cardiology of Careggi Hospital, Florence, Italy, in whom plate-
let reactivity was prospectively assessed by light transmittance aggregometry.
Interventions All patients received 325 mg of aspirin and a loading dose of 600 mg
of clopidogrel followed by a maintenance dosage of 325 mg/d of aspirin and 75mg/d
of clopidogrel for at least 6 months. Patients with HRPR as assessed by adenosine di-
phosphate test (70% platelet aggregation) received an increased dose of clopido-
grel (150-300 mg/d) or switched to ticlopidine (500-1000 mg/d) under adenosine di-
phosphate test guidance.
MainOutcomeMeasures The primary end point was a composite of cardiac death,
myocardial infarction, any urgent coronary revascularization, and stroke at 2-year follow-
up. Secondary end points were stent thrombosis and each component of the primary
end point.
Results The primary end point event rate was 14.6% (36/247) in patients with HRPR
and 8.7% (132/1525) in patients with low residual platelet reactivity (absolute risk
increase, 5.9%; 95% CI, 1.6%-11.1%; P=.003). Stent thrombosis was higher in the
HRPR group compared with the low residual platelet reactivity group (6.1% [15/247]
vs 2.9% [44/1525]; absolute risk increase, 3.2%; 95% CI, 0.4%-6.7%; P=.01). By
multivariable analysis, HRPRwas independently associated with the primary end point
(hazard ratio, 1.49; 95% CI, 1.08-2.05; P=.02) and with cardiac mortality (hazard
ratio, 1.81; 95% CI, 1.18-2.76; P=.006).
Conclusion Among patients receiving platelet reactivity–guided antithromboticmedi-
cation after PCI, HRPR status was significantly associated with increased risk of ische-
mic events at short- and long-term follow-up.
Trial Registration clinicaltrials.gov Identifier: NCT01231035
JAMA. 2011;306(11):1215-1223 www.jama.com
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activity after clopidogrel loading is an
independent prognostic marker of risk
of long-term thrombotic events in pa-
tients with ACS undergoing an inva-
sive procedure and receiving long-
term antithrombotic treatment adjusted
according to the results of platelet func-
tion tests.
METHODS
Study Design
We performed a prospective, observa-
tional, single-center cohort study of
consecutive patients with ACS under-
going an invasive procedure in whom
platelet reactivity after clopidogrel load-
ing was prospectively assessed.
Patient Population
Consecutive patients undergoing coro-
nary stent implantation for ACS from
April 2005 to April 2009 at the Divi-
sion of Cardiology of Careggi Hospi-
tal, Florence, Italy, were enrolled in this
study. Acute coronary syndromes in-
cluded unstable angina with ST-
segment changes, non–ST-segment el-
evation acute myocardial infarction, and
ST-segment elevation acute myocar-
dial infarction (STEMI). All patients
were considered eligible for the study
irrespective of clinical presentation of
ACS or coronary anatomy.
Thus, patients with multivessel dis-
ease requiring multivessel intervention
in the same procedure or in a staged pro-
cedure were included. The only exclu-
sion criteria were in-hospital death that
was not due to stent thrombosis and an-
ticipated nonadherence to dual antiplate-
let treatment for at least 6 months.
The study was approved by the lo-
cal ethics committee. All patients gave
written informed consent.
Platelet Reactivity Assessment
Platelet reactivity assessment was made
by light transmittance aggregometry
(APACT4, Helena Laboratories, Mi-
lan, Italy) using adenosine diphos-
phate (ADP) as an agonist. Blood
samples anticoagulated with 0.109M so-
dium citrate (ratio, 9:1) were ob-
tained 12 to 18 hours after a 600-mg
clopidogrel loading dose. For patients
receiving both the loading dose of clopi-
dogrel and a glycoprotein IIb/IIIa in-
hibitor in the catheterization labora-
tory, blood samples were obtained after
6 days, while patients were receiving a
75-mg/d maintenance dosage of clopi-
dogrel and 325 mg/d of aspirin. Platelet-
rich plasma, obtained by centrifuging
whole blood for 10 minutes at 200g, was
stimulated with 10µM ADP. The 100%
line was set using platelet-poor plasma
and the 0 baseline established with
platelet-rich plasma (adjusted from
180109/L to 300109/L). Platelet ag-
gregation (according to the Born
method) was evaluated considering the
maximal percentage of platelet aggre-
gation in response to stimulus. The co-
efficient of variation of ADP platelet ag-
gregation was 6.8%.6,8,9 High residual
platelet reactivity by ADP test was de-
fined as platelet aggregation of 70% or
greater.6
PCI and Antiplatelet Management
All interventions were performed ac-
cording to current standards, and the
type of stent implanted and the use of
glycoprotein IIb/IIIa inhibitors were at
the discretion of the operator. All pa-
tients received 325 mg of aspirin and a
loading dose of 600 mg of clopidogrel
followed by a maintenance dosage of
325 mg/d of aspirin and 75 mg/d of
clopidogrel for at least 6 months. Pa-
tients taking a maintenance regimen of
ticlopidine or clopidogrel at the time of
admission received a reloading dose of
600 mg of clopidogrel. Patients with
high residual platelet reactivity by ADP
test received an increased long-term
dosage of clopidogrel (150-300 mg/d)
or switched to ticlopidine (500-1000
mg/d) under ADP test guidance, with
the goal of reaching an ADP test result
of less than 70% platelet aggregation.
End Points
The primary end point of the study
was a composite of ischemic events
including cardiac death, myocardial
infarction, any urgent coronary revas-
cularization, and stroke at 2-year
follow-up. Patients with more than 1
event were assigned the highest-
ranked event according to the previ-
ous list. Key secondary end points
were stent thrombosis, defined accord-
ing to the Academic Research Consor-
tium criteria,15 and the individual
components of the primary end point.
All deaths were considered cardiac
unless an unequivocal noncardiac
cause could be documented. Myo-
cardial infarction definition included
the following criteria: electrocardio-
graphic changes consistent with myo-
cardial infarction or cardiac bio-
marker elevation (creatine kinase–MB
or troponin I 3 times higher than the
upper normal limit on 2 measure-
ments) or cardiac biomarker reeleva-
tion in patients with pre-PCI values
higher than the upper normal limits
(at least 50% higher than the previous
nadir, with documentation that car-
diac biomarkers were decreasing
before PCI). Urgent coronary revascu-
larization included intervention due
to recurrence of ACS. Stroke was
defined as an acute neurological defi-
cit lasting more than 24 hours.
All events were adjudicated by an
event adjudication committee whose
members (R.M., P.B., and R.A.) were
blinded for platelet function data.
Follow-up
All patients had scheduled examina-
tions at 1, 6, and 12 months and then
annually thereafter. Adherence to an-
tiplatelet treatment was assessed dur-
ing scheduled or unscheduled exami-
nations. All other possible information
derived from hospital readmission or
by the referring physician, relatives, or
municipality live registries were en-
tered into the prospective database.
Statistical Analysis
Based on the results of the RECLOSE
1 study,6 the current study was pow-
ered to demonstrate an increase in the
primary end point from an expected
10% in patients with low residual plate-
let reactivity by ADP test to 20% in pa-
tients with high residual platelet reac-
tivity. With this assumption, the
statistical power was greater than 90%
based on a maximum sample size of
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1298 patients for the primary end point
and 1596 for cardiac mortality.
Discrete data are summarized as fre-
quencies and continuous data are ex-
pressed as means and standard devia-
tions or medians and interquartile
ranges (IQRs) as appropriate. The 2
test was used for comparison of cat-
egorical variables, and the unpaired,
2-tailed t test or Mann-Whitney rank
sum test was used to test differences
among continuous variables. To con-
trol for type I error in multiple com-
parisons, the Bonferroni-adjusted sig-
nificance level was used for the 5
secondary end point outcomes. Sur-
vival curves were generated with the
Kaplan-Meier method, and the differ-
ence between groups was assessed by
log-rank test. A landmark analysis was
computed by the Kaplan-Meier method
for the primary end point and for car-
diac mortality using a starting point of
6 months after the index procedure. We
selected the 6-month point as a land-
mark according to the prespecified ex-
clusion criterion of anticipated nonad-
herence to dual antiplatelet treatment
for at least 6 months.
The outcomes of 6-month event-
free (primary end point or cardiac
death) patients were evaluated at lon-
ger-term follow-up in the 2 study
groups. The multivariable analyses to
evaluate the independent contribu-
tion of clinical, angiographic, proce-
dural, and platelet reactivity variables
to the primary end point and cardiac
mortality were performed by the for-
ward stepwise Cox proportional haz-
ards model. High platelet reactivity ac-
cording to the chosen criterion (ADP
test result70%) was entered as a di-
chotomous variable. The other vari-
ables entered into the model were as fol-
lows: age, male sex, body mass index
of 30 or higher, smoking, diabetes melli-
tus, hypertension, hypercholesterol-
emia, history of myocardial infarc-
tion, serum creatinine level higher than
1.50 mg/dL (to convert values to
µmol/L, multiply by 88.4), left ven-
tricular ejection fraction of less than
40%, Killip class of III or IV on admis-
sion, 3-vessel coronary disease, use of
drug-eluting stents, total stent length,
multivessel PCI, and use of abcix-
imab. The proportional hazard assump-
tion was assessed and satisfied graphi-
cally by plotting log (−log) survival
curves against log survival time for each
predictor category and verifying
whether curves were parallel, and in ad-
dition, using time-dependent covari-
ates. Cox regression analysis was per-
formed to assess time-dependent
covariates. No significant time-
dependent predictor was found. Mul-
ticollinearity was assessed using col-
linearity diagnostics. The variance
inflation factors showed no signifi-
cant collinearity among the covariates
(2.0). The Cox proportional haz-
ards model was used to test interac-
tion among covariates. A propensity
score analysis was performed with a lo-
gistic regression model from which the
probability for high residual platelet re-
activity to the ADP test was calculated
for each patient. The variables that were
significantly different between the 2
groups and those that are known to
affect platelet reactivity were incorpo-
rated in the model: age, male sex, body
mass index of 30 or higher, smoking,
diabetes mellitus, hypertension, hyper-
cholesterolemia, family history of coro-
nary artery disease, history of myocar-
dial infarction, serum creatinine level
higher than 1.50 mg/dL, left ventricu-
lar ejection fraction less than 40%, Kil-
lip class of III or IV on admission, 3-ves-
sel coronary disease, previous PCI,
previous coronary surgery, and STEMI.
Model discrimination was assessed with
the C statistic and goodness of fit with
the Hosmer-Lemeshow test. Thereaf-
ter, a Cox multivariate analysis was per-
formed to adjust high residual platelet
reactivity for propensity score used as
a continuous covariate.
A propensi ty score–matched
analysis (3:1) was also performed
because of the expected differences
in baseline characteristics between
patients with high and low residual
platelet reactivity. An optimal data
matching technique without replace-
ment was performed with a random
order using the radius-matching
algorithm for propensity score differ-
ence with a caliper of 0.5. Bias reduc-
tion was assessed by comparing the
standardized difference for propen-
sity score and the other covariates
before and after matching between
the 2 groups (a value 10% after
matching indicates inconsequential
imbalance). After matching, the stan-
dardized difference for propensity
score changed from 53.3% to 4.8%
and for the other covariates to less
than 10%. Two-year outcomes for
the primary end point, cardiac mor-
tality, and stent thrombosis were
assessed after matching by 2 test.
The risk of overfitting was controlled
by using a ratio of at least 1:10 for
the number of explanatory variables
and sample size. In addition, in the
second Cox multivariable model, the
adjustment of high residual platelet
reactivity for propensity score (using
2 covariates) minimized the overfit-
ting risk. P.05 was considered sta-
tistically significant. All tests were
2-sided. Analyses were performed
with SPSS software, version 19 (IBM
Corp, Somers, NY).
RESULTS
From April 2005 to April 2009, 1931
consecutive patients admitted for ACS
underwent PCI at Careggi Hospital
(FIGURE 1). Among these patients, 1789
were enrolled in the study, while 142
were excluded for the following rea-
sons: anticipated nonadherence to dual
antiplatelet treatment (93 patients), un-
availability of platelet function tests be-
cause of in-hospital death due to car-
diogenic shock or congestive heart
failure, or thrombocytopenia (48 pa-
tients), and refusal to participate (1 pa-
tient). Baseline patient characteristics
are presented in TABLE 1. The inci-
dence of high residual platelet reactiv-
ity by ADP test after clopidogrel load-
ing was 14%. Patients with high residual
platelet reactivity were older than pa-
tients with low residual platelet reac-
tivity and had a higher incidence of dia-
betes mellitus, hypercholesterolemia,
and history of previous myocardial in-
farction, while STEMI was more fre-
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quent in the low residual platelet reac-
tivity group. Moreover, congestive heart
failure and a left ventricular ejection
fraction of less than 40% were more fre-
quent in the high residual platelet re-
activity group.
The median value of ADP test re-
sults after clopidogrel loading was 41%
(IQR, 24%-54%) in the low residual
platelet reactivity group and 76% (IQR,
72%-81%) in the high residual plate-
let reactivity group. Among patients
with high residual platelet reactivity af-
ter clopidogrel loading, the median
value of the ADP test result decreased
to 64% (IQR, 54%-75%; P .001) after
treatment adjustment, but 94 patients
(38%) still had an ADP test result of
70% or greater.TABLE 2 summarizes the
angiographic and procedural charac-
teristics.
Follow-up
The 2-year follow-up rate was 99% (me-
dian follow-up length, 2.8 years [IQR,
2.3-3.7 years]). The follow-up rates
were 99.6% and 98.9% (P=.31) in pa-
tients with and without high residual
platelet reactivity, respectively. At 6
months, adherence to dual antiplate-
let treatment was very high: 97% of pa-
tients were taking aspirin and a thieno-
pyridine (97% of the low residual
platelet reactivity group and 99% of the
high residual platelet reactivity group).
At a median follow-up of 2.8 years, 952
patients (63%) in the low residual plate-
let reactivity group and 168 patients
(68%) in the high residual platelet re-
activity group were taking 2 antiplate-
let agents. Most patients in both groups
took statins, -blockers, and angioten-
sin-converting enzyme inhibitors that
were prescribed according to the rec-
ommendations of current guidelines.
Clinical Outcome
TABLE 3 summarizes the 2-year clini-
cal outcome. The primary end point
event rate was 14.6% (36/247) in the
high residual platelet reactivity group
and 8.7% (132/1525) in the low re-
sidual platelet reactivity group (abso-
lute risk increase, 5.9%; 95% CI, 1.6%-
11.1%; P=.003). Negative and positive
Figure 1. Study Flow
247 With follow-up at 24 mo included in
analysis of primary end point 
1525 With follow-up at 24 mo included in
analysis of primary end point 
1789 Patients enrolled
1931 Consecutive patients undergoing
coronary stent implantation for acute
coronary syndromes
248 Had high residual platelet reactivity on
platelet aggregation test and received
increased clopidogrel dosage or switched
to ticlopidine
1541 Had low residual platelet reactivity on
platelet aggregation test and continued
maintenance dosage
1 Lost to follow-up
0 Lost at 6-month follow-up 
1 Lost at 24-month follow-up
16 Lost to follow-up
1 Lost at 6-month follow-up 
15 Lost at 24-month follow-up
142 Excluded
93 Had anticipated nonadherence to dual
antiplatelet treatment (including 29 patients
with STEMI who died in hospital)
48 Unavailability of platelet tests
1 Refused to participate
STEMI indicates ST-elevation myocardial infarction.
Table 1. Baseline Characteristics
Characteristics
No. (%) of Participantsa
P
Valueb
Total
(N = 1789)
LRPR
(n = 1541)
HRPR
(n = 248)
Age, mean (SD), y 69.0 (11.8) 68.6 (11.8) 71.7 (11.3) .001
Aged75 y 664 (37) 537 (35) 127 (51) .001
Male 1423 (80) 1232 (80) 191 (77) .29
Body mass index, mean (SD)c 26.3 (3.8) 26.3 (3.8) 26.6 (3.9) .25
Body mass index30c 295 (16) 249 (16) 46 (18) .35
Smokers 437 (24) 389 (25) 48 (19) .045
Hypertension 1021 (57) 870 (56) 151 (61) .19
Diabetes mellitus 355 (20) 285 (19) 70 (28) .001
Hypercholesterolemia 801 (45) 667 (43) 134 (54) .002
Previous myocardial infarction 324 (18) 254 (16) 70 (28) .001
Previous PCI 273 (15) 226 (15) 47 (19) .08
Previous coronary surgery 91 (5) 75 (5) 16 (6) .29
ST-elevation acute myocardial infarction 829 (46) 747 (48) 82 (33) .001
Creatinine1.50 mg/dL 188 (10) 160 (10) 28 (11) .67
LVEF, mean (SD), % 45.3 (11.3) 45.6 (11.1) 43.1 (12.3) .001
LVEF40% 552 (31) 455 (29) 97 (39) .002
Killip class III-IV 104 (6) 89 (6) 15 (6) .87
ADP test result, median (range), % 46 (27-61) 41 (24-54) 76 (72-81) .001d
Aspirin at discharge 1747 (98) 1508 (98) 239 (96) .15
Clopidogrel at discharge 1789 (100) 1541 (100) 248 (100) .99
Warfarin at discharge 36 (2) 31 (2) 5 (2) .99
Statin at discharge 1628 (91) 1408 (91) 220 (89) .17
Proton pump inhibitor at discharge 1181 (66) 1012 (66) 169 (68) .46
Abbreviations: ADP, adenosine diphosphate; HRPR, high residual platelet reactivity; LRPR, low residual platelet reactivity;
LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
aData are expressed as No. (%) of participants unless otherwise indicated.
bThe 2 test was used for comparison of categorical variables and the unpaired 2-tailed t test for continuous variables
unless otherwise indicated.
cCalculated as weight in kilograms divided by height in meters squared.
dComparison between groups was performed by the Mann-Whitney rank sum test.
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predictive values were 91% (95% CI,
90%-93%) and 15% (95% CI, 11%-
20%), respectively. The difference in the
primary end point event rate was driven
by the difference in cardiac mortality,
which was 9.7% in the high residual
platelet reactivity group and 4.3% in the
low residual platelet reactivity group
(absolute risk increase, 5.5%; 95% CI,
1.9%-9.7%;P .001); there were no dif-
ferences in the other components of the
primary end point. Among patients with
high residual platelet reactivity after
clopidogrel loading, there were no dif-
ferences either in the primary end point
rate or in cardiac mortality among pa-
tients with an ADP test result of less
than 70% after treatment adjustment vs
patients with a persistent ADP test re-
sult of 70% or greater (primary end
point event rates, 14.4% and 14.9%, re-
spectively; P= .91; cardiac mortality
rates, 8.5% and 11.7%, respectively;
P= .41). FIGURE 2 shows the long-
term estimated risk of the primary end
point and cardiac mortality. The esti-
mated risk of a primary end point event
was 27.5% (95% CI, 18.3%-36.7%) in
the high residual platelet reactivity
group and 14.5% (95% CI, 12.1%-
16.9%) in the low residual platelet re-
activity group (P .001). The esti-
mated risk of cardiac mortality was
12.7% (95% CI, 8.3%-17.1%) in the
high residual platelet reactivity group
and 6.9% (95% CI, 5.4%-8.4%) in the
low residual platelet reactivity group
(P .001). The landmark analysis using
the prespecified starting point of 6
months showed that the differences be-
tween groups in the primary end point
and in cardiac mortality emerged both
in the short-term follow-up as well as
from 6 months to long term (FIGURE 3).
In the entire study population, the
stent thrombosis rate was 3.3% (59/
1772) (Table 3). The stent thrombosis
rate was 2-fold higher in the high re-
sidual platelet reactivity group (6.1%
[15/247] vs 2.9% [44/1525]; absolute
risk increase, 3.2%; 95% CI, 0.4%-
6.7%; P=.01).
By multivariable analysis, high re-
sidual platelet reactivity was indepen-
dently associated with the primary end
point (hazard ratio [HR], 1.49; 95% CI,
1.08-2.05; P= .02) and with cardiac
mortality (HR, 1.81; 95% CI, 1.18-
2.76; P = .006) (TABLE 4) and re-
mained significantly associated with the
primary end point and cardiac mortal-
ity after propensity score adjustment (C
statistic, 0.65; 95% CI, 0.62-0.69;P=.81
for Hosmer-Lemeshow test): the HR for
primary end point events was 1.47 (95%
CI, 1.06-2.04; P=.02) and the HR for
cardiac mortality was 1.63 (95% CI,
1.06-2.51; P=.03). No significant in-
teraction was found between high re-
sidual platelet reactivity and the other
covariates. In the propensity score–
matched analysis that included 992 pa-
tients (100% of the high residual plate-
Table 2. Angiographic and Index Procedure Characteristics
Characteristics
No. (%) of Participantsa
P Valueb
Total
(N = 1789)
LRPR
(n = 1541)
HRPR
(n = 248)
Multivessel coronary disease 1020 (57) 858 (56) 162 (65) .004
3-Vessel disease 487 (27) 405 (26) 82 (33) .03
Thrombus-containing lesions 561 (31) 495 (32) 66 (27) .08
Multivessel PCI 551 (31) 455 (29) 96 (39) .004
2-Vessel PCI 411 (23) 343 (22) 68 (27)
3-Vessel PCI 128 (87) 103 (7) 25 (10)
Treated vessel
Left anterior descending artery 938 (52) 793 (51) 145 (58) .04
Right coronary artery 710 (40) 614 (40) 96 (39) .74
Circumflex coronary artery 597 (33) 503 (33) 94 (38) .10
Left main 125 (7) 103 (7) 22 (9) .20
Ramus 57 (3) 48 (3) 9 (4) .67
Thrombectomy 417 (23) 370 (24) 47 (19) .08
No. of stents per patient,
mean (SD)
1.8 (1.1) 1.8 (1.1) 1.9 (1.1) .09
Total stent length, mean (SD),
mm
32.9 (26.0) 32.4 (25.9) 36.0 (26.5) .04
Treatment with drug-eluting
stent
917 (51) 784 (51) 133 (54) .42
Abciximab use 1227 (69) 1064 (69) 163 (66) .30
Hospital length of stay,
mean (SD), d
3.6 (3.1) 3.5 (3.0) 4.1 (3.7) .005
Abbreviations: HRPR, high residual platelet reactivity; LRPR, low residual platelet reactivity; PCI, percutaneous coronary
intervention.
aData are expressed as No. (%) of participants unless otherwise indicated.
bThe 2 test was used for comparison of categorical variables and the unpaired 2-tailed t test for continuous variables.
Table 3. Two-Year Clinical Outcomes
Outcomes
No. (%) of Participants
P Valuea
Total
(n = 1772)
LRPR
(n = 1525)
HRPR
(n = 247)
Primary end point 168 (9.5) 132 (8.7) 36 (14.6) .003
Cardiac death 89 (5) 65 (4.3) 24 (9.7) .001
Myocardial infarction 41 (2.3) 33 (2.2) 8 (3.2) .30
Urgent coronary revascularization 16 (0.9) 15 (1.0) 1 (0.4) .71b
Stroke 22 (1.2) 19 (1.2) 3 (1.2) .99b
Stent thrombosis 59 (3.3) 44 (2.9) 15 (6.1) .01
Definite 30 (1.7) 23 (1.5) 7 (2.8) .13
Probable 15 (0.8) 11 (0.7) 4 (1.6) .15
Possible 14 (0.9) 10 (0.7) 4 (1.6) .11
Abbreviations: HRPR, high residual platelet reactivity; LRPR, low residual platelet reactivity.
aThe 2 test was used for comparison unless otherwise indicated.
bBy Fisher exact test.
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let reactivity group and 48% of the low
residual platelet reactivity group were
successfully matched) (TABLE 5), the
2-year primary end point event rate and
cardiac mortality rate were signifi-
cantly higher in the high residual plate-
let reactivity group compared with the
low residual platelet reactivity group
(primary end point event rate, 14.6%
[36/246] vs 9.2% [68/737]; P=.02 and
cardiac mortality rate, 9.7% [24/246]
vs 5.3% [39/737]; P=.01). Again, in the
matched cohort, the stent thrombosis
rate was higher in patients with high
residual platelet reactivity compared
with patients with low residual plate-
let reactivity (6.1% [15/246] vs 3.1%
[23/737], respectively; P=.04).
COMMENT
The main findings of this study can be
summarized as follows: (1) The inci-
dence of high residual platelet reactiv-
ity using ADP as an agonist after a
600-mg clopidogrel loading dose in pa-
tients with ACS undergoing an inva-
sive procedure is relatively low (14%);
(2) residual platelet reactivity remains
high in 38% of patients after treat-
ment adjustment with first-genera-
tion thienopyridines; (3) normaliza-
tion of the ADP test result after
treatment adjustment is not associ-
ated with a better outcome vs a persis-
tent abnormal ADP test result; and (4)
high residual platelet reactivity after
Figure 2. Kaplan-Meier Survival Curves for Primary End Point Events and for Cardiac Mortality in Patients With HRPR and LRPR
Log-rank P<.001
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HRPR 247 230 219 213 193 147 80 64 37 10
Log-rank P<.001
No. at risk
180 360 540 720 900 1080 1260 1440 1620
LRPR 1525 1466 1441 1418 1364 1059 645 476 262 91
Time, d
Cardiac mortality
HRPR 247 234 226 221 203 156 84 67 41 12
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Figure 3. Kaplan-Meier Landmark Analysis Survival Curves for Primary End Point Events and for Cardiac Mortality Beginning at 6 Months in
Patients With HRPR and LRPR
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clopidogrel loading is associated with
increased risk of short- and long-term
ischemic events, including stent throm-
bosis.
The incidence of 14% of high re-
sidual platelet reactivity as revealed in
this study is consistent with previous
studies using light transmittance ag-
gregometry, 10µM of ADP as an ago-
nist, and a cutoff value of 70%.6,8,9 Un-
like previous studies that included
patients with stable coronary artery dis-
ease, this study included only patients
with ACS, who may have higher base-
line platelet reactivity vs stable pa-
tients. The finding of similar inci-
dence of high residual platelet reactivity
in this study suggests that the poten-
tial difference in baseline platelet reac-
tivity between patients with stable coro-
nary artery disease and those with ACS
Table 4. Univariable and Multivariable-Adjusted Predictors of Long-term Primary End Point Events and Cardiac Death
Variables
No. of
Events/
No. of
Participantsa
Unadjusted
Hazard Ratio
(95% CI)
P
Valueb
Multivariable-Adjusted
Hazard Ratio
(95% CI)
P
Valueb
Primary End Point
HRPR 49/247 1.82 (1.33-2.50) .001 1.49 (1.08-2.05) .02
Age, mean (SD), per y 74 (11) 1.05 (1.04-1.06) .001 1.04 (1.03-1.05) .001
Male sex 169/1411 0.76 (0.56-1.03) .08
Body mass index30c 31/292 0.92 (0.63-1.34) .66
Smokers 45/431 0.75 (0.54-1.04) .08
Diabetes mellitus 57/355 1.38 (1.02-1.86) .04
Hypertension 129/1015 1.01 (0.78-1.32) .92
Hypercholesterolemia 97/792 0.94 (0.72-1.23) .66
Family history of coronary
disease
11/121 0.66 (0.36-1.22) .18
History of myocardial infarction 67/322 2.02 (1.51-2.68) .001 1.50 (1.12-2.02) .007
Creatinine1.5 mg/dL 38/185 1.77 (1.25-2.50) .003 1.52 (1.07-2.17) .02
LVEF40% 114/548 2.52 (1.94-3.27) .001 1.67 (1.25-2.23) .001
Killip class III-IV on admission 32/103 3.41 (2.34-4.96) .001 2.43 (1.62-3.64) .001
3-Vessel coronary disease 86/486 1.72 (1.31-2.25) .001
Use of abciximab 162/1218 1.24 (0.93-1.67) .15
Use of drug-eluting stents 127/913 1.04 (0.80-1.36) .76
Total stent length, mean (SD), mm 38 (30) 1.01 (1.01-1.02) .004
Multivessel PCI 90/549 1.50 (1.15-1.96) .003
Cardiac Death
HRPR 29/247 2.24 (1.47-3.42) .001 1.81 (1.18-2.76) .006
Age, mean (SD), per y 77 (10) 1.08 (1.06-1.10) .001 1.06 (1.04-1.08) .001
Male sex 85/1411 0.76 (0.49-1.17) .21
Body mass index30c 10/292 0.54 (0.28-1.04) .07
Smokers 20/431 0.65 (0.40-1.05) .08
Diabetes mellitus 37/355 1.99 (1.34-2.95) .001
Hypertension 75/1015 1.49 (1.01-2.20) .045
Hypercholesterolemia 54/792 1.14 (0.79-1.65) .49
Family history of coronary
disease
6/121 0.74 (0.32-1.67) .47
History of myocardial infarction 35/322 2.08 (1.40-3.10) .001
Creatinine1.5 mg/dL 26/185 2.57 (1.66-3.98) .001 1.91 (1.22-2.99) .005
LVEF40% 69/548 3.76 (2.57-5.48) .001 2.16 (1.43-3.26) .001
Killip class III-IV on admission 21/103 4.50 (2.80-7.23) .001 2.72 (1.63-4.52) .001
3-Vessel coronary disease 55/486 2.59 (1.79-3.75) .001 1.74 (1.19-2.54) .004
Use of abciximab 83/1218 1.30 (0.86-1.98) .22
Use of drug-eluting stents 66/913 1.15 (0.79-1.68) .46
Total stent length, mean (SD), mm 39 (31) 1.01 (1.01-1.02) .01
Multivessel PCI 55/549 2.13 (1.47-3.08) .001
Abbreviations: HRPR, high residual platelet reactivity; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
aContinuous variables are presented as mean (SD) in patients who had a primary end point event or cardiac death.
bBy Cox proportional hazards model.
cCalculated as weight in kilograms divided by height in meters squared.
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has no effect on in vitro tests after the
loading dose of 600 mg of clopidogrel.
Other studies using light transmit-
tance aggregometry with a different
dose of ADP and a lower cutoff or other
methods report a higher incidence of
high residual platelet reactivity, with a
resulting lower positive predictive value
of the test.5,10,11,16 In the GRAVITAS trial,
which reported an incidence of 40.7%
high platelet reactivity after clopido-
grel loading, the observational com-
parison of patients with and without
high on-treatment reactivity as as-
sessed by VerifyNow (Accumetrics, San
Diego, California) showed an in-
creased number of ischemic events in
the former group, but the difference did
not reach statistical significance.16
Platelet aggregation functional test–
driven antiplatelet treatment enhance-
ment using an increased dose of clopi-
dogrel or a switch to ticlopidine may
result in an ADP test result of less than
70% in approximately 60% of patients
without an effect on clinical outcome.
This finding is consistent with the
results of the GRAVITAS trial, the first
concluded large-scale study assessing
the clinical impact of doubling a long-
term dosage of clopidogrel in PCI
patients with high residual platelet
reactivity after clopidogrel loading.16
In the GRAVITAS trial, which enrolled
mainly patients with stable coronary
artery disease, the increased mainte-
nance dosage of clopidogrel (150 mg)
was associated with a modest but sig-
nificant reduction in platelet reactivity
as assessed by VerifyNow, but this in
vitro effect was not associated with a
reduction in the rate of ischemic
events compared with patients receiv-
ing a standard (75-mg) maintenance
dosage of the drug. Previous smaller
studies of adjusted therapy under the
guidance of in vitro tests have shown
that adjunctive clopidogrel reloading
or use of glycoprotein IIb/IIIa inhibi-
tors may be beneficial. However, these
studies focused only on short-term
clinical events.17-20
To our knowledge, this is the first
study to explore the association of high
residual platelet reactivity after clopi-
dogrel loading with long-term clinical
outcome in patients with ACS under-
going an invasive procedure. Acute
coronary syndromes have been associ-
ated with a diminished platelet re-
sponse to clopidogrel with spontane-
ous decrement of platelet reactivity after
the early period of ACS and interven-
tion.21,22 In this study, the landmark
analysis for the primary end point and
cardiac death using a prespecified start-
ing point at 6 months after the index
procedure shows that the prognostic
strength of a single measurement of re-
sidual platelet reactivity during ACS is
maintained at long-term follow-up. This
finding supports the hypothesis that
high residual platelet reactivity after
600-mg clopidogrel loading is an inde-
pendent prognostic marker of short-
and long-term ischemic events.
Consistent with previous studies, our
study shows that high residual plate-
let reactivity is likely to be associated
with a worse patient risk profile. How-
ever, after adjusting for differences in
baseline characteristics between low
and high residual platelet reactivity
groups, high residual platelet reactiv-
ity remained an independent predic-
tor of cardiac death.
Our study must be evaluated in light
of some limitations. First, the data de-
rive from a prospective nonrandom-
ized registry. We used propensity score
matching to make the patient groups
comparable according to the mea-
sured confounders. However, residual
unmeasured confounding cannot be ex-
cluded. Second, despite the difference
in stent thrombosis rates between
groups, the study was not powered for
this adverse event. Third, it is un-
known if nonantiplatelet drugs and ad-
herence to recommended drugs may
have influenced the long-term out-
come. Fourth, this study adjusted an-
tiplatelet therapy using an increased
maintenance dosage of clopidogrel or
ticlopidine. It is unknown if high re-
sidual platelet reactivity after 600-mg
clopidogrel loading in patients under-
going PCI for ACS is a nonmodifiable
risk factor for thrombotic events or if
tailored therapy with use of new anti-
thrombotic agents such as prasugrel or
ticagrelor, which provide more potent
and predictable in vitro platelet aggre-
gation inhibition, have a positive effect
on clinical outcome.23-25 Thus, the re-
sults of this study should be consid-
ered only as hypothesis generating for
further studies of tailored therapy using
new antithrombotic agents.
Table 5. Baseline Characteristics of Propensity-Matched Groups
Characteristics
No. (%) of Participantsa
P
Valueb
LRPR
(n = 744)
HRPR
(n = 248)
Age, mean (SD), y 71.7 (10.9) 71.7 (11.3) .43
Age 75 y 343 (45) 127 (51) .16
Male 559 (75) 191 (77) .55
Smokers 147 (20) 48 (19) .89
Hypercholesterolemia 398 (53) 134 (54) .88
Diabetes mellitus 199 (27) 70 (28) .65
Hypertension 442 (59) 151 (61) .68
Previous PCI 145 (19) 47 (19) .85
Previous myocardial infarction 204 (27) 70 (28) .81
Previous coronary surgery 49 (7) 16 (6) .94
3-Vessel disease 243 (33) 82 (33) .91
LVEF 40% 284 (38) 97 (39) .79
Killip class III-IV 41 (6) 15 (6) .75
ST-elevation acute
myocardial infarction
254 (34) 82 (33) .76
Abbreviations: HRPR, high residual platelet reactivity; LRPR, low residual platelet reactivity; LVEF, left ventricular ejec-
tion fraction; PCI, percutaneous coronary intervention.
aData are expressed as No. (%) of participants unless otherwise indicated.
bThe 2 test was used for comparison of categorical variables and the unpaired 2-tailed t test for continuous variables.
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